UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders

This publication has 52 references indexed in Scilit:

• Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis
  The FASEB Journal, 2005
• Anandamide transport
  Pharmacology & Therapeutics, 2004
• The therapeutic potential of cannabis in multiple sclerosis
  Expert Opinion on Investigational Drugs, 2003
• Changes in cannabinoid CB₁ receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis
  Synapse, 2001
• Loss of normal huntingtin function: new developments in Huntington's disease research
  Trends in Neurosciences, 2001
• Endocannabinoids control spasticity in a multiple sclerosis model
  The FASEB Journal, 2000
• Unsaturated Long-Chain N-Acyl-vanillyl-amides (N-AVAMs): Vanilloid Receptor Ligands That Inhibit Anandamide-Facilitated Transport and Bind to CB1 Cannabinoid Receptors
  Biochemical and Biophysical Research Communications, 1999
• CANNABINOID RECEPTORS AND THEIR ENDOGENOUS AGONISTS
  Annual Review of Pharmacology and Toxicology, 1998
• Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function
  Brain Research, 1995
• Effects of Repeated Administration of Estradiol Benzoate on Tubero‐Infundibular GABAergic Activity in Male Rats
  Journal of Neurochemistry, 1985